The dose-limiting salivary gland toxicity of 225Ac-labelled PSMA for treatment of metastatic, castration-resistant prostate cancer remains unresolved. Suppressing the metabolism of the gland by intraparenchymal injections of botulinum toxin appears to be a promising method to reduce off-target uptake. A 68Ga-PSMA PET/CT scan performed 45 days after injection of 80 units of botulinum toxin A into the right parotid gland in a 63-year-old patient showed a decrease in the SUVmean in the right parotid gland of up to 64% as compared with baseline. This approach could be a significant breakthrough for radioprotection of the salivary glands during PSMA radioligand therapy.
CITATION STYLE
Baum, R. P., Langbein, T., Singh, A., Shahinfar, M., Schuchardt, C., Volk, G. F., & Kulkarni, H. (2018). Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept. Nuclear Medicine and Molecular Imaging, 52(1), 80–81. https://doi.org/10.1007/s13139-017-0508-3
Mendeley helps you to discover research relevant for your work.